HALCYON BIOMEDICAL, INC.

FRIENDSWOOD, TX · Medtech · Private

Microfluidic device for high-throughput cell separation and isolation in cell therapy manufacturing

Grants
$2.4M
5 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Developing a paper-based diagnostic test for sickle cell disease$224,885
Federal grantDepartment of Health and Human Services · Phase II · Developing a paper-based diagnostic test for sickle cell disease$497,654
Federal grantDepartment of Health and Human Services · Phase II · Developing a paper-based diagnostic test for sickle cell disease$499,906
Federal grantNational Science Foundation · Phase I · SBIR Phase I: A New Approach for Isolating Leukocyte Sub-populations to Enable Efficient Manufacturing of Cellular Therapies$225,000
Federal grantNational Science Foundation · Phase II · SBIR Phase II: A New Approach for Isolating Leukocyte Sub-populations to Enable Efficient Manufacturing of Cellular Therapies$948,852
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1805AFFINERGY, LLC——
1806CORAMI BIOTECH INC.—$230K
1807CLEAVED DIAGNOSTIC CORPORATION——
1808HALCYON BIOMEDICAL, INC.——
1809Savage Medical Inc.——
1810G5 BIOLOGICAL INNOVATIONS LLC——
1811THERMOBIONICS LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.